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Stress Impacts the Regulation Neuropeptides in the Rat
Hippocampus and Prefrontal Cortex
Wenxue Li, Aurelie Papilloud, Laura Lozano-Montes, Nan Zhao, Xueting Ye,
Xiaozhe Zhang,* Carmen Sandi, and Gregor Rainer
Adverse life experiences increase the lifetime risk to several stress-related
psychopathologies, such as anxiety or depressive-like symptoms following
stress in adulthood. However, the neurochemical modulations triggered by
stress have not been fully characterized. Neuropeptides play an important role
as signaling molecules that contribute to physiological regulation and have
been linked to neurological and psychiatric diseases. However, little is known
about the inﬂuence of stress on neuropeptide regulation in the brain. Here,
we have performed an exploratory study of how neuropeptide expression at
adulthood is modulated by experiencing a period of multiple stressful
experiences. We have targeted hippocampus and prefrontal cortex (PFC) brain
areas, which have previously been shown to be modulated by stressors,
employing a targeted liquid chromatography-mass spectrometry (LC-MS)
based approach that permits broad peptide coverage with high sensitivity. We
found that in the hippocampus, Met-enkephalin, Met-enkephalin-Arg-Phe,
and Met-enkephalin-Arg-Gly-Leu were upregulated, while Leu-enkephalin and
Little SAAS were downregulated after stress. In the PFC area,
Met-enkephalin-Arg-Phe, Met-enkephalin-Arg-Gly-Leu, peptide PHI-27,
somatostatin-28 (AA1-12), and Little SAAS were all downregulated. This
systematic evaluation of neuropeptide alterations in the hippocampus and
PFC suggests that stressors impact neuropeptides and that neuropeptide
regulation is brain-area speciﬁc. These ﬁndings suggest several potential
peptide candidates, which warrant further investigations in terms of
correlation with depression-associated behaviors.
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1. Introduction
Stress helps individuals to cope with
hostile conditions, enhancing their prob-
ability of survival. However, continued or
repeated exposure to stress can lead to
long-lasting negative eﬀects on brain
functioning and mental health, such as
anxiety and depression.[1,2] For example,
convergent evidence suggests that stress
during adulthood reduces social behav-
iors while increases aggression. Impor-
tantly, similar eﬀects have been demon-
strated when animals experience stress
during neurodevelopmental periods,
such as for example, peripubertal stress
inhibits social interactions during
adulthood. Stressors during both devel-
opmental periods and adulthood lead to
changes in neuronal networks.[3–6] It has
thus been shown that peripubertal stress
results in modulations of gene and cell
adhesion molecule expression in pre-
frontal cortex (PFC) during adulthood,[4,6]
and adulthood stressors also modulate
hippocampal functioning.[5] Both hip-
pocampus and PFC are also involved in
cognitive and emotional processing of
stress stimuli,[7,8] and both hippocampus
and PFC mediate the symptoms of
depression and anxiety.[9,10] Given that stress can lead to depres-
sion and anxiety, we aim to further explore the neurochemical
changes on the hippocampus and PFC in adult rats that expe-
rienced multiple stressors during both development as well as
adulthood. These neurochemical changes are likely to contribute
to anxiety and depressive symptoms after stress exposure.
Over the past 30 years, evidence has emerged regarding the
role of neuropeptides as signaling molecules in the nervous
system.[11–13] Furthermore, it has been suggested that neuropep-
tide signaling is of special importance for stress responses,
as peptides might not be used under normal circumstances,
but play a critical role in the nervous system’s adaptation to
stress.[13–17] Neuropeptides are 50 times larger than neurotrans-
mitters (from 2 to 100 amino acids) and often contain multiple
receptor recognition sites.[18] Therefore, they have higher binding
aﬃnity (in the order of nmol L−1, while neurotransmitters bind
in the order of μmol L−1).[18] All of these characteristics make
neuropeptides highly attractive for drug development, since the
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enhanced selectivity might permit highly selective pharmacolog-
ical interventions, for example with antagonists, with lower risk
for unwanted non-speciﬁc side eﬀects.[18] Recently, a substance
P receptor (neurokinin 1) antagonist has thus been developed
as treatment for major depressive disorder, acting as an eﬃcient
serotonin reuptake inhibitor with reduced side eﬀects.[19–21] Addi-
tional neuropeptide receptor ligands are currently under clinical
trials for several neurological and mental health disorders.[22]
Here, we aim to study the eﬀects of a combination of devel-
opmental and adulthood stressors on changes on the hippocam-
pal and prefrontal neuropeptides. This study is of speciﬁc impor-
tance as it could highlight the role of novel therapeutic targets
for stress induced neurological disorders (such as anxiety and de-
pression). Previous studies on the eﬀects of stress in neuropep-
tides have mainly used techniques such as radioimmunoassay or
in situ hybridizations for detection of mRNA expression, which
are targets for one or a few speciﬁc neuropeptides. The use of
mass spectrometry (MS) to identify the neuropeptides by con-
trast allows us to determine the exact sequence (including post-
translationalmodiﬁcations) of all the neuropeptides diﬀerentially
expressed in our brain region of interest. MS-based neuropep-
tidomic analysis has successfully resulted in high identiﬁcation
rates of mouse neuropeptides,[23] and we have developed speciﬁc
techniques allowing broad coverage neuropeptide monitoring in
rat and tree shrew animal models.[24,25] Indeed, stress is already
known to inﬂuence neuropeptide expression in speciﬁc brain
regions.[3,26–30] As discussed above, a majority of previous stud-
ies linking stress with changes on neuropeptides have focused
on analyzing changes on one speciﬁc neuropeptide.
Given that hundreds of neuropeptides have been
identiﬁed,[15–18,31,32] it is desirable to obtain a more complete
picture of how these signaling molecules are aﬀected by stress,
particularly since it is thought that peptides may often act in a
concerted, synergistic manner to mediate biological functions.[33]
Therefore, identifying the whole range of neuropeptides in the
brain region of interest will provide a comprehensive view on
the role of neuropeptides on stress responses and will increase
the chances of identifying novel pharmacological targets for the
treatments of stress-related disorders.
2. Experimental Section
2.1. Animals
Subjects were the oﬀspring of Wistar Han rats (Charles River
Laboratories, France), bred locally in the animal facility. They
were kept on a 12 h light–dark cycle (lights on at 0700 h). Food
and water were available ad libitum. All procedures were con-
ducted in conformity with the SwissNational Institutional Guide-
lines on Animal Experimentation and approved by a license
from the Swiss Cantonal VeterinaryOﬃceCommittee for Animal
Experimentation.
2.2. Experimental Design
Male rats from diﬀerent litters were distributed into diﬀerent
home cages in groups of two to three non-siblings 21 d after birth
(P21) and each cage was randomly assigned to control (CTRL, six
animals) or peripubertal stress (PPS, six animals) conditions. At
P28, animals underwent the well-established peripubertal stress
protocol previously developed in Professor Sandi’s lab.[34–39] PPS
group was exposed to two fear-inducing stressors: the synthetic
fox odor trimethylthiazoline (Phero Tech, Delta, BC, Canada) ad-
ministered in a plastic box (38× 27.5× 31 cm) and exposure to an
elevated platform (12 × 12 cm) presented in a variable schedule
in a span of 7 d across the P28–P42 period. Each stressor lasted
for 25 min.
At adulthood, PPS animals followed acute restraint stress
procedure for 1 h before sacriﬁce while control animals were
left undisturbed. Acute restraint stress was induced as follows:
rats were gently wrapped in a paper towel to minimize the
risk of injuries and restrained 1 h in wire mesh restrainers
(26× 26 cm2) in their home cages. Following the sacriﬁce, brains
were rapidly extracted, the hippocampus and PFC parts were dis-
sected within 2min and immediately denaturedwith theDenator
heat irradiation (Denator AB, Gothenburg, Sweden) as described
elsewhere.[40] The denatured tissues were put in the liquid ni-
trogen rapidly and then transferred to −80 °C refrigerator until
analysis.
2.3. Sample Preparation
The neuropeptides were extracted using a dual phase method
for mixing on column (MOC) analysis as introduced in our
previous publication.[41] To minimize interference from protein
fragmentation, temperature was controlled during all extraction
procedures.[42] Each sample was extracted twice, with 0.2% acetic
acid (Fluka, Buchs, Switzerland) aqueous solution and 30% ace-
tonitrile (Optima grade, Thermo Fisher) containing 0.2% acetic
acid solution. The extraction solution was 5 μL per 1 mg brain
tissue. A homogenization step was performed on a Precellys
24 homogenizer (Bertin Technologies, Montigny-le-Bretonneux,
France) twice for 1 min, and then ultra-sonication for 10 min at
20 °C. The sample was centrifuged at 20 000 × g for 1 h at 4 °C.
After extraction, the supernatant was ﬁltered on a 10 kDa cut-
oﬀ ﬁlter (Vivacon 500, Sartorious AG, Goettingen, Germany) by
centrifuging for approximately 90 min at 14 000 × g at 4 °C. The
dual phase extracts were loaded separately and then mixed on
the column for nanoLC-MS analysis. The organic extracts were
injected into a trap column ﬁrst, and after 5 min the aqueous
extracts were also injected such that both extracts were eluted
together through the nanoLC-MS system and detected. The in-
jection volume was 10 μL and per sample running was almost
90 min.
2.4. LC-MS Data Acquisition
The extracts of hippocampus and PFC were analyzed on a LTQ-
Discovery (Thermo Fisher scientiﬁc, Bremen, Germany) tandem
with Dionex Ultimate 3000 Nano LC system (Dionex, Thermo
Fisher, Sunnyvale, USA). In the LC-MS analysis, the on trap
column-mix method was introduced as before.[41] The 2 cm trap
column and 25 cm analytical column was packed with ReproSil-
Pur C18 AQ particles (100 A˚, Dr. Maisch GmbH) 5 and 3 μm,
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Figure 1. Correlation and volcano plots. A) Biological and technical replicate correlations by ion intensity exported from Progenesis QI for Pro-
teomics program (Nonlinear), which show good reproducibility for label-free neuropeptides quantiﬁcation; B,C) volcano plots of signiﬁcantly changed
neuropeptides in the hippocampus and PFC, respectively. Numbers used here are linked to those in Figure 2, Figure 3, and Table 1. There are
22 and 18 signiﬁcant changed neuropeptides detected in hippocampus and PFC brain regions in peripubertal stress animals compared with
controls.
respectively. The empty analytical capillary (75 μm ID, 360 μm
OD, with 8 μm emitter tip) was purchased from New Objec-
tive (Cambridge, USA). The loading pump was always washed
with 98% water and 1.98% acetonitrile containing 0.2% formic
acid. The loading status was set to 3 min and then switched to
injection position until 80 min. The NC pump mobile phase
consisted of water:acetonitrile:formic acid of 98:1.98:0.2 and wa-
ter:acetonitrile:formic acid of 1.98:98:0.2 for A and B, respec-
tively. The elution was performed at ﬂow rate 300 nL min−1 with
90 min gradient proﬁle as follows: 0–3 min, 5% B; 3–7 min, 5–
20% B; 7–35 min, 20–30% B; 30–55 min, 30–45% B; 55–60 min,
45–55%B; 60–65min, 55–90%B; 65–80min, 90% B, and the last
10 min for equilibration with 5% B.
2.5. Diﬀerential Analysis and Targeted Analysis for Peptide
Identiﬁcation
For the quantiﬁcation analysis, all the hippocampus (n = 6 for
each animal group) and PFC (n = 6 for each animal group)
samples were arranged alternating treatment samples and
controls, and each sample was analyzed in two replicates. For
improving quantiﬁcation accuracy, quality control samples (QCs)
derived froma mixture of treatments and controls (each 20 μL),
were used (four QCs for hippocampus and PFC, at the begin-
ning and end of the sequence). For the diﬀerential analysis, the
full scan was acquired from 350–2000 m/z with Orbitrap an-
alyzer with resolve power 30 000. The lock mass (445.120025
from polydimethylcyclosiloxane) was used for real-time inter-
nal recalibration.[43] In diﬀerential analysis, the Progenesis for
proteomics software (Nonlinear Dynamic, Newcastle, UK) was
used for the ion intensity extraction for treatments, controls,
and QCs and exported as CSV ﬁles. The unpaired t-test be-
tween treatment and control group was performed, and the
level of statistical signiﬁcance was set at p < 0.05 (n = 6).
Signiﬁcantly, peptide ions were rejected if the coeﬃcient vari-
ation was greater than 50% for QCs (n = 4). After ﬁlter, the
ions were exported as CSV ﬁle and imported into the inclu-
sion list with 3 min of the retention window for further targeted
LC-MS/MS analysis, by which the peptides were selected for
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collision-induced dissociation (CID) fragmentation. Acquisition
on LC-MS instrument consisted of a full MS scan event and three
MS/MS scan events at mass range from 350–2000 m/z, and the
setting of resolve power 30 000 for MS and MS/MS acquisition.
Minimum signal threshold was set as 100 000, and isolation win-
dow was 2 m/z. Normalized collision energy was 30%. For the
dynamic exclusion setting, the repeat count of 2, exclusion, and
repeat duration time of 30 s, 50 ppm tolerance for precursor se-
lection with disabled previewmode for full MS scan and disabled
monoisotopic precursor selection mode.
2.6. Data Analysis
The PEAKS Studio 5.3 (BSI, Waterloo, Ontario, Canada), which
has Data Reﬁnement, Auto De Novo, and Peaks Search func-
tions, was used for the spectral interpretation of all raw MS/MS
data ﬁles.[44,45] The mass tolerance of precursor ions and prod-
ucts were speciﬁed to 10 ppm and 0.05 Da, respectively. No
enzyme was selected for the database search. Variable post-
translational modiﬁcations, including amidation (C-terminal),
acetylation (N-terminal), pyroglutamylation from glutamic acid,
and glutamine (N-terminal) were selected for de novo sequenc-
ing. The Uniprot rat database (January 4, 2016) was speciﬁed for
the database search after de novo sequencing. The cutoﬀ of false
discovery rate for peptide identiﬁcation in Peaks Search was 1%.
After that, the manual check was used for inspecting identiﬁed
neuropeptides.[41]
3. Results
The purpose of this study was to proﬁle the alteration of
neuropeptides in rat hippocampus and PFC in animals sub-
jected to multiple stressors compared to control animals
(not subjected to stress). We estimated the technical and
biological replicates, taking into account both instrument-
related and biological variability, that showed good repro-
ducibility in peptides quantitative analysis (Figure 1A). In
summary, hippocampus neuropeptide diﬀerential analysis re-
sults revealed 22 signiﬁcant changed neuropeptides (non-paired
t-test, p < 0.05, see Figure 1B) derived from four precur-
sors secretogranin-1, proenkephalin-A (PENK), cerebellin-1, and
ProSAAS. Of these modulated neuropeptides, 14 of them
were upregulated and eight were downregulated in the stress
treatment compared with controls (Figure 2 and Table 1).
In PFC, 18 neuropeptides (non-paired t-test, p < 0.05, see
Figure 1B) exhibited stress-related modulations. These peptides
were derived from seven precursors: secretogranin-1, PENK,
cholecystokinin (CCK), vasoactive intestinal peptide (VIP), so-
matostatin, ProSAAS, and Pro-melanin-concentrating hormone
(Pro-MCH). Of these neuropeptides, seven were upregulated
Figure 2. Histogram for signiﬁcantly changed neuropeptides detected in the hippocampus after peripubertal stress treatment (T) comparedwith controls
(C). The labeled numbers are linked to those in Figure 1B volcano plots and Table 1. The complete list of neuropeptide information is shown in Supporting
Information Table 1.
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Table 1. Signiﬁcantly changed neuropeptides in the hippocampus and PFC brain regions in peripubertal stress treatment animals compared with controls.
No. Precursor Peptide Name p-value
Hippocampus 1 Secretogranin-1 R.SFARAPHLDL.K 0.033
2 Secretogranin-1 R.YPQSKWQEQ.E 0.017
3 Secretogranin-1 L.DEGHDPVHESPVDTA.K 0.012
4 Secretogranin-1 R.LLDEGHDPVHESPVDTA.K 0.036
5 Secretogranin-1 R.QYDDGVAELDQLLHY.R 0.032
6 Secretogranin-1 R.LLDEGHDPVHESPVDT.A 0.035
7 Secretogranin-1 F.DPLQWKNSDFE.K 0.013
8 Secretogranin-1 Y.DDGVAELDQLLHY.R 0.017
9 Proenkephalin-A R.YGGFL.K Leu-enkephalin 0.04
10 Proenkephalin-A K.YGGFM.K Met-enkephalin 0.047
11 Proenkephalin-A R.YGGFMRF Met-enkephalin-Arg-Phe 0.028
12 Proenkephalin-A R.YGGFMRGL.K Met-enkephalin-Arg-Gly-Leu 0.043
13 Proenkephalin-A R.SPQLEDEAKELQ.K 0.042
14 Cerebellin-1 R.SGSAKVAFSAIRSTNH.E 0.006
15 Cerebellin-1 R.SGSAKVAFSAIRSTN.H 0.005
16 Cerebellin-1 S.GSAKVAFSAIRSTNH.E 0.039
17 Cerebellin-1 S.GSAKVAFSAIRSTN.H 0.025
18 ProSAAS S.APLAETSTPLRL.R 0.037
19 ProSAAS R.AVPRGEAAGAVQELA.R 0.018
20 ProSAAS R.SLSAASAPLAETSTPL.R 0.047
21 ProSAAS L.SAASAPLAETSTPLRL.R 0.039
22 ProSAAS R.SLSAASAPLAETSTPLRL.R Little SAAS 0.047
Prefrontal cortex 1 Secretogranin-1 R.SFARAPHLDL.K 0.043
5 Secretogranin-1 R.QYDDGVAELDQLLHY.R 0.045
8 Secretogranin-1 Y.DDGVAELDQLLHY.R 0.023
23 Secretogranin-1 R.Q(-17.03)YDDGVAELDQLLHY.R 0.021
24 Secretogranin-1 R.LGALFNPYFDPLQWKNSDFE.K 0.044
25 Proenkephalin-A R.VGRPEWWMDYQ.K 0.049
11 Proenkephalin-A R.YGGFMRF Met-enkephalin-Arg-Phe 0.015
12 Proenkephalin-A R.YGGFMRGL.K Met-enkephalin-Arg-Gly-Leu 0.035
26 Cholecystokinin R.AVLRPDSEPRARLGALLA.R 0.001
27 Cholecystokinin R.AVLRPDSEPRARLGALL.A 0.044
28 Cholecystokinin R.MSVLKNLQGLDPSHRISD.R 0.035
29 Cholecystokinin V.LRPDSEPRARLGALL.A 0.022
30 Cholecystokinin R.LGALLARYIQQVR.K 0.043
31 Cholecystokinin K.NLQGLDPSHRISD.R 0.044
32 Vasoactive intestinal peptide R.HADGVFTSDYSRLLGQISAKKYLESLI(-.98).G Instestinal peptide PHI-27 0.048
33 Somatostatin R.SANSNPAMAPRE.R Somatostatin-28(AA1-12) 0.016
22 ProSAAS R.SLSAASAPLAETSTPLRL.R Little SAAS 0.001
34 Pro-MCH E.IGDEENSAKFPI(-.98).G 0.037
The neuropeptide numbers are linked to those in Figure 1 volcano plots and histograms in Figures 2 and 3. The complete neuropeptide information is shown in Supporting
Information Table 1
and 11 downregulated following the stressors (see Figure 3 and
Table 1). The representative MS/MS spectrums for neuropep-
tides were shown at Figure 4. The complete list of identiﬁed and
quantiﬁed neuropeptides are shown in Supporting Information,
Tables 1 and 2.
The largest group of neuropeptides aﬀected by stress in
the hippocampus were derived from the secretogranin-1
precursor (n = 8). Four of these were downregulated including
R.SFARAPHLDL.K (−55%, p = 0.033), L.DEGHDPVHESPV-
DTA.K (−69%, p = 0.012), R.QYDDGVAELDQLLHY.R (−42%,
p= 0.032), and Y.DDGVAELDQLLHY.R (−75%, p= 0.017), while
another four were upregulated including R.YPQSKWQEQ.E
(96%, p = 0.017), R.LLDEGHDPVHESPVDTA.K (115%,
p = 0.036), R.LLDEGHDPVHESPVDT.A (92%, p = 0.035), and
F.DPLQWKNSDFE.K (106%, p = 0.013). In PFC neuropeptides,
ﬁve neuropeptides derived from secretogranin-1 precursor
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Figure 3. The histogram for signiﬁcant changed neuropeptides detected in PFC after peripubertal stress treatment (T) compared with controls (C).
The labeled numbers are linked to those in Figure 1C volcano plot and Table 1. The complete list of neuropeptide information is shown in Supporting
Information Table 1.
Figure 4. The representative MS/MS spectrums for neuropeptides identiﬁcation with PEAKs studio. A, Met-enkephalin-Arg-Phe; B, Met-enkephalin-Arg-
Gly-Leu; C and D neuropeptides cleaved from precursor Cholecystokinin (CCK).
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were aﬀected by stress, and four of these being
upregulated including R.SFARAPHLDL.K (106%,
p = 0.043), R.QYDDGVAELDQLLHY.R (84%, p = 0.045),
Y.DDGVAELDQLLHY.R (78%, p = 0.023), and R.Q(-17.03)
YDDGVAELDQLLHY (105%, p = 0.021), while only the single
peptide R.LGALFNPYFDPLQWKNSDFE.K was downregu-
lated −92% (p = 0.044). It has been reported that peptides
derived from secretogranin-1 precursor: SEESQEREY, SFARA-
PQLD, LLDEGHDPVHESPIDTA, and LLDEGHYPV were
downregulated in mouse hypothalamus after antidepres-
sant imipramine treatment.[46] Note that the rat peptide
R.LLDEGHDPVHESPVDTA.K we detected here is highly sim-
ilar to the previously documented mouse peptide LLDEGHD-
PVHESPIDTA, having only one amino acid diﬀerence that
probably reﬂects organism variation. The second largest
group of stress-modulated neuropeptides in the hippocampus
was derived from the PENK precursor with four of them
upregulated including Met-enkephalin (77%, p = 0.047),
Met-enkephalin-Arg-Phe (161%, p = 0.028), Met-enkephalin-
Arg-Gly-Leu (96%, p = 0.043), R.SPQLEDEAKELQ.K (97%,
p = 0.042), and peptide Leu-enkephalin downregulated −49%
(p = 0.04). Of the peptide family, three altered peptides were
detected in the PFC and all of these were downregulated:
R.VGRPEWWMDYQ.K, Met-enkephalin-Arg-Phe, and Met-
enkephalin-Arg-Gly-Leu at −69% (p = 0.049),−52% (p = 0.015),
and −84% (p = 0.035), respectively. Additional modulated
peptides belonged to diverse families. In the hippocampus, four
peptides derived from cerebellin-1 precursor were observed,
all of which were upregulated: R.SGSAKVAFSAIRSTNH.E
(104%, p = 0.006), R.SGSAKVAFSAIRSTN.H (107%,
p = 0.005), S.GSAKVAFSAIRSTNH.E (200%, p = 0.039),
and S.GSAKVAFSAIRSTN.H (54%, p = 0.025). Previous mouse
hypothalamic peptides research has revealed decreased levels
of SGSAKVAFSAIRSTNH, SGSAKVAFSAIRSTN, and GSAK-
VAFSAIRSTN after imipramine treatment.[46] We document
for the ﬁrst time an involvement of ﬁve ProSAAS precur-
sor derived peptides in the brain stress response. Peptides
R.SLSAASAPLAETSTPL.R, L.SAASAPLAETSTPLRL.R, and
R.SLSAASAPLAETSTPLRL.R (Little SAAS) were downregulated
−23% (p = 0.047), −40% (p = 0.039), and −59% (p = 0.047), re-
spectively. S.APLAETSTPLRL.R and R.AVPRGEAAGAVQELA.R
were upregulated 62% (p = 0.037) and 63% (p = 0.018), re-
spectively. In the PFC, we also observed six altered peptides
derived from the CCK precursor and the levels of three of them
were upregulated. Peptides R.AVLRPDSEPRARLGALLA.R,
R.AVLRPDSEPRARLGALL.A, and V.LRPDSEPRARLGALL.A
were upregulated 132% (p = 0.001), 78% (p = 0.044), and 59%
(p = 0.022), respectively, and R.MSVLKNLQGLDPSHRISD.R,
R.LGALLARYIQQVR.K, and K.NLQGLDPSHRIS D.R were
downregulated −59% (p = 0.035), −38% (p = 0.043) and
−41% (p = 0.044), respectively. This observation is con-
sistent with previous results implicating CCK neurotrans-
mission in anxiogenic and depressogenic eﬀects of social
stress.[28,47,48] We found that intestinal peptide PHI-27
(R.HADGVFTSDYSRLLGQISAKKYLESLI(-.98).G), derived
from VIP precursor, was downregulated −41% (p = 0.048) in
the PFC. VIP has been implicated in modulating emotional
processes or adaptive responses to stressful stimuli in rat model
of depression.[49] Somatostatin-28 (AA1-12) was downregulated
−78% (p = 0.016) in brain PFC following stress. The Little
SAAS (R.SLSAASAPLAETSTPLRL.R) peptide derived from
ProSAAS was also downregulated −70% (p = 0.001) in PFC. In
addition to this, peptide E.IGDEENSAKFPI(-.98).G derived from
Pro-MCH precursor was also downregulated −48% (p = 0.037)
in the PFC region. It has been reported that the neuropeptide
MCH plays a role in rapid eye movement (REM) sleep and
is involved in the pathophysiology of depression.[50] Some
authors have demonstrated that MCH receptor-1 antagonist
(SNAP-7941) possesses antidepressant and anxiolytic eﬀects in
animal models of depressive disorder.[51–54] In addition, repeated
chronic mild stress could increase the levels of gene expression
of MCH receptor-1 in mice hippocampus and this was reversed
by chronic ﬂuoxetine treatment.[55] Besides, the importance of
MCHergic system in depressive disorder was emphasized in
a recent study, indicating that an upregulation on the level of
preproMCH expression and a decrease of MCH receptor could
be a biomarker of the severity of depressive disorders.[56] These
results suggest that MCHergic system, precursors, or produced
neuropeptides are related to certain aspects of major depressive
disorder.
4. Discussion
The peptidomics approach for the diﬀerential analysis has an ex-
clusive advantage compared with other methods, which allows
simultaneous detection and identiﬁcation of a large number of
peptides and provides the ability to diﬀerentiate between unique
peptides derived from the same precursor. It is important to note
that in neuropeptide analysis, where there is no enzyme diges-
tion, all of the detected peptide ions are of endogenous origin
and may thus contribute to a better understanding of the un-
derlying neurobiological processes. Developing novel pharma-
cological strategies to treat psychiatric disorders is thus an im-
portant current direction in neurobiology, and a large body of
evidence suggests that neuropeptides may play a critical role in
these diseases.[57]
The hypothalamic-pituitary-adrenal (HPA) axis participates in
the stress response and plays a key role in maintenance of
homeostasis.[58] Moreover, HPA dysregulation has been linked to
depression.[59] The hippocampus and PFC are highly susceptible
to stress.[60,61] A decreased metabolism in the PFC is a frequently
replicated ﬁnding inmajor depressive disorder.[61,62] Here, we use
quantiﬁed diﬀerential analysis for hippocampus and PFC neu-
ropeptide detection and quantiﬁcation in the rat after multiple
stressors. In total, we observed only a limited number of neu-
ropeptides impacted by stress, some of which were consistent
with previous reports whereas others were demonstrated here
for the ﬁrst time to be linked to stress. A group of neuropep-
tides derived from secretogranin-1 (LLDEGHYPVRESPIDTA),
cerebellin-1 (SGSAKVAFSAIRSTNH), and somatostatin precur-
sors were downregulated in the mouse hypothalamus after an-
tidepressant imipramine acute or chronic treatment[46]; accord-
ingly, in the present study we found upregulation of all of these
peptides in hippocampus and PFC after stressors. Therefore,
our results were consistent with previous literature, given that
stressors can trigger depression, it is expected that antidepres-
sant treatment regulates neuropeptides in the opposite way that
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stressors do. This is a very relevant result given that it high-
lights a potential neurobiological mechanism by which stressors
could lead to depression. Furthermore, it shows the consistency
of the secretogranin-1, cerebellin-1, and somatostatin precursor
regulation between diﬀerent brain regions: hypothalamus, PFC,
and hippocampus in diﬀerent animal species (mice and rats,
respectively).
The opioid peptide enkephalin is an important modulator of
stress responses,[63] and our ﬁndings support this, as members
of its family were strongly modulated by stressor application.
It has been reported that enkephalin knockout male mice ap-
pear to be resistant to chronic mild stress,[29] and PENK knock-
out mice exhibit abnormal stress reactivity and increased anx-
iety behavior in acute stress situations.[64,65] In wild-type mice,
PENK gene expression levels are increased in the PFC, hip-
pocampus, and other brain areas, but decreased in the amyg-
dala following chronic mild stress.[29] Furthermore, chronic mild
stress signiﬁcantly decreases levels of Met-enkephalin in the
rat nucleus accumbens.[66] It has been previously demonstrated
that key enkephalin-derived neuropeptides Leu-enkephalin, Met-
enkephalin, Met-enkephalin-Arg-Phe, and Met-enkephalin-Arg-
Gly-Leu were upregulated by chronic nicotine treatment in rat
dorsal striatum.[41] Many of these peptides were also aﬀected by
stress in the present study, partially in a similar, and partially
in opposite directions as in the chronic nicotine study. This in-
dicates substantial overlap in neuropeptide regulatory mecha-
nisms between nicotine consumption and stress, which is inter-
esting given that both of these experiences can trigger depressive
episodes in humans.
Related to enkephalins, the present results highlight two novel
aspects of neuropeptide regulation. First, it shows that members
of the same neuropeptide family can be both up- and downregu-
lated in a given brain area following stressors. This emphasizes
the power of MS-based approaches, in that we can provide the ex-
act amino acid sequence of each modulated peptide. Our ﬁnding
reinforces the idea that neuropeptides are coregulated, but that
this regulation is complex and probably involves multiple excita-
tory and inhibitory interactions among compounds of the same
peptide family. Second, we show clearly that peptide expression
in diﬀerent brain areas following stressor is not regulated in the
same way, but rather there are speciﬁc aspects that may be char-
acteristic of how each brain structure in the network responds to
stress. For example, we see that while in the hippocampus the
majority of enkephalin-derived peptides are upregulated, all of
the ones detected in the PFC were downregulated. This obser-
vation suggests that the synthesis and release of neuropeptides
is not brain-wide, but speciﬁc to brain regions. Our results have
important implications for the designing of peptides as potential
drug targets; major functional brain regions should be studied
independently avoiding the assumption that neuropeptide regu-
lation follows the same patterns over the whole brain.
To our knowledge, alterations of intestinal peptide PHI-27
(VIP) in the PFC following stress are reported for the ﬁrst time
in the present study. It is however known that hippocampal
VIP-positive neurons contribute to modulating emotional pro-
cesses or adaptive responses to stressful stimuli in a rat model
of depression.[49,67] Decades ago, it was also reported that VIP
decreases in the cerebrospinal ﬂuid in atypical depression.[68] VIP
enhances both pre- and postsynaptic GABA-ergic transmission
in hippocampal interneurons, leading to increased excitatory
synaptic transmission to CA1 pyramidal cells,[69] a mechanism
that modulates neuronal excitability in the rat hippocampus.[70]
Finally, we also observed neuropeptides derived from the precur-
sor CCK in this study, consistent with an involvement of CCK-
ergic neurotransmission in both anxiogenic and depressogenic
eﬀects of social stress.[28] CCK thus contributes to PFC regula-
tion of depression and anxiety-like behaviors, and CCK receptor
blockade in medial PFC induces a resilient phenotype, whereas
CCK administration intomedial PFCmimics the anxiogenic- and
depressogenic-like eﬀects of social stress.[47] Available evidence
thus supports a role of CCK in the regulation of depression and
anxiety, but the mechanism needs to be further clariﬁed.
5. Conclusion
This is the ﬁrst study that uses theMS-based quantitativemethod
to proﬁle alterations in a broad range of neuropeptides in the rat
hippocampus and PFC after stressor treatment. This method is
able to high throughput detect and quantify peptides including
their corresponding post-transnational modiﬁcations, which is
not achieved by others biochemical methods currently. With the
label free relative quantiﬁcation strategy, we found several signiﬁ-
cant changes in classic neuropeptides in hippocampus and PFC,
including Met-enkephalin, somatostatin, VIP, and correspond-
ing derivative peptides. Most of these peptides exhibit consistent
regulation with previous described stress animal models. These
results reveal that the brain responses to stressful episodes are
multifaceted and involves brain region speciﬁc modulations of
peptide regulation. Our ﬁndings provide a novel and compre-
hensive approach to evaluate neurochemical circuits in animal
models related to stress or other related disorders, for example,
depression. The detected peptides can now be examined in terms
of their links with behavioral symptoms and underlying neural
circuits, paving the way for potential biomarker discovery or new
pharmacological strategies for treatment of stress-related disor-
ders in the future.
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